市场消息：在《新英格兰医学杂志》发表的完整iii期研究结果显示，礼来(LLY.N)的口服肥胖症药物Orforglipron显示出令人信服的疗效和安全性，与注射GLP-1药物一致。

Core Insights - The study published in the New England Journal of Medicine presents compelling efficacy and safety results for Eli Lilly's oral obesity drug Orforglipron, comparable to injectable GLP-1 medications [1] Company Summary - Eli Lilly's Orforglipron demonstrates significant therapeutic potential in treating obesity, aligning with the performance of existing injectable GLP-1 drugs [1]